Price Action To Observe: What’s Propelling Ultragenyx Pharmaceutical Inc to Increase So Much?

Price Action To Observe: What's Propelling Ultragenyx Pharmaceutical Inc to Increase So Much?

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! About 668,663 shares traded hands or 8.22% up from the average. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 1.51% since April 8, 2016 and is uptrending. It has underperformed by 4.13% the S&P500.
The move comes after 8 months positive chart setup for the $3.63B company. It was reported on Nov, 10 by Barchart.com. We have $96.58 PT which if reached, will make NASDAQ:RARE worth $834.90 million more.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on November, 14. They expect $-1.58 EPS, down 53.40% or $0.55 from last year’s $-1.03 per share. After $-1.46 actual EPS reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 8.22% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 12 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ultragenyx Pharmaceutical Inc has been the topic of 20 analyst reports since July 27, 2015 according to StockzIntelligence Inc. As per Tuesday, August 18, the company rating was downgraded by Zacks. The stock has “Buy” rating given by H.C. Wainwright on Tuesday, February 9. The firm has “Sell” rating by Citigroup given on Thursday, September 3. The firm has “Neutral” rating by Citigroup given on Tuesday, January 12. Leerink Swann initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Friday, February 19. Leerink Swann has “Outperform” rating and $80 price target. The firm earned “Buy” rating on Monday, July 13 by SunTrust. The rating was initiated by Jefferies on Friday, October 23 with “Buy”. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, June 8. The company was initiated on Tuesday, September 1 by Raymond James. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) earned “Buy” rating by Stifel Nicolaus on Tuesday, December 1.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment decreased to 0.97 in Q2 2016. Its down 0.12, from 1.09 in 2016Q1. The ratio is negative, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Creative Planning last reported 0% of its portfolio in the stock. Quantbot Lp owns 7,391 shares or 0.04% of their US portfolio. Vanguard Group Inc has invested 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Adage Capital Partners Limited Liability Company has 638,500 shares for 0.09% of their US portfolio. Price T Rowe Incorporated Md has 0.02% invested in the company for 1.59 million shares. California Employees Retirement Systems accumulated 42,900 shares or 0% of the stock. Teacher Retirement Sys Of Texas last reported 5,085 shares in the company. Tiaa Cref Management Ltd Liability Corp has invested 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Rs Inv Llc owns 20,000 shares or 0.01% of their US portfolio. Axa holds 0.05% or 227,213 shares in its portfolio. The Maryland-based Columbia Prtnrs L L C Inv Mgmt has invested 0.02% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Paloma Partners Mgmt last reported 0% of its portfolio in the stock. Moreover, Pnc Ser has 0% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 200 shares. Services Automobile Association has invested 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). The British Columbia – Canada-based Pacad Inv Limited has invested 0.08% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment